Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

PolandBack to Poland

Clinical trials in Poznan – page 68

943 clinical trials in Poznan, Poland across 11 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

PolandOur site in PolandBadaniaKliniczne.pl(opens in a new tab)
Poznan at a glance
943
clinical trials
  • Research sites11
Type of trial
Recruitment status
Quick filters

943 trials in Poznan

Open in trial search

Non-small cell lung cancer

Not recruiting

Study on the Effectiveness and Safety of Alectinib, Entrectinib, and a Drug Combination for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Colitis ulcerative

Not recruiting

Long-Term Safety Study of Obefazimod for Patients with Moderate to Severe Ulcerative Colitis

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Obefazimod
  • Sponsor:Abivax

Pulmonary hypertension

Not recruiting

Study on the Effectiveness and Safety of Ralinepag for Patients with Pulmonary Arterial Hypertension

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Ralinepag
  • Sponsor:United Therapeutics Corp.

Non-small cell lung cancer

Not recruiting

Study of Amivantamab and Lazertinib Combination vs. Osimertinib vs. Lazertinib for First-Line Treatment in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Amivantamab
  • Sponsor:Janssen Cilag International

Clear cell papillary renal cell carcinoma

Not recruiting

Study Comparing Savolitinib and Durvalumab with Sunitinib and Durvalumab for Patients with Advanced Papillary Renal Cell Carcinoma

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

Non-small cell lung cancer+2

Not recruiting

Study Comparing Lorlatinib and Crizotinib for Patients with Advanced ALK-Positive Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years
  • Substances:Lorlatinib
  • Sponsor:Pfizer Inc.

Pulmonary hypertension

Not recruiting

Study on the Long-term Safety and Efficacy of Ralinepag for Patients with Pulmonary Arterial Hypertension

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Ralinepag
  • Sponsor:United Therapeutics Corp.

Crohn's disease

Not recruiting

Study on the Effectiveness and Safety of Risankizumab for Patients with Moderate to Severe Crohn's Disease

Investigational
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Fabry's disease

Not recruiting

Study of venglustat tablets to reduce neuropathic and abdominal pain in patients aged 16 and older with Fabry disease who are untreated or haven't received treatment for 6 months

Investigational
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Venglustat
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Relapsing multiple sclerosis

Not recruiting

Study on the Effectiveness and Safety of Remibrutinib Compared to Teriflunomide for Patients with Relapsing Multiple Sclerosis

Registered drug
Countries:PolandPoland
  • Participants:18–64 years
  • Substances:Charcoal, Activated
  • Sponsor:Novartis Pharma AG

Hormone-dependent prostate cancer

Not recruiting

Study of Capivasertib and Abiraterone for Patients with Metastatic Hormone-Sensitive Prostate Cancer with PTEN Deficiency

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:AstraZeneca AB

Psoriatic arthropathy

Not recruiting

Study on Tildrakizumab for Patients with Active Psoriatic Arthritis Who Have Not Used Anti-TNF Therapy

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Tildrakizumab
  • Sponsor:Iqvia Biotech Limited

Other cities in Poland

The busiest research cities in the country

All 239 cities in Poland

Clinical research in Poznan

What the registry says about research in the country

01 Immunology & Infectious Diseases

Clinical trials focusing on meningococcal vaccines and respiratory syncytial virus prevention. Studies include testing new conjugate vaccines in infants and evaluating immune responses in older adults.

  • Meningococcal infection prevention
  • RSV vaccination studies
  • Vaccine immunogenicity assessment

Multiple age groups are being studied to ensure comprehensive protection against infectious diseases.

02 Dermatology & Rheumatology

Innovative research into psoriatic conditions and inflammatory skin disorders. Studies evaluating new treatments for plaque psoriasis and psoriatic arthritis.

  • Moderate to severe plaque psoriasis
  • Psoriatic arthritis treatments
  • Atopic dermatitis therapy

Focus on developing targeted therapies for chronic inflammatory skin conditions.

03 Oncology

Advanced research in bladder cancer and other oncological conditions. Studies combining immunotherapy with traditional treatments for enhanced efficacy.

  • Non-muscle invasive bladder cancer
  • Metastatic prostate cancer
  • Gastric cancer treatments

Investigating novel combination therapies and targeted treatments for various cancer types.

04 Chronic Diseases

Comprehensive studies addressing chronic kidney disease, obesity, and cardiovascular conditions. Research focuses on innovative treatment approaches and disease management.

  • Heart failure prevention
  • Obesity management
  • Chronic kidney disease treatment

Evaluating new therapeutic options for long-term disease management and prevention.

Back to PolandAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.